Compare Stocks: HLVX, KMDA, CMPX, and LXEO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$2.31 +2.7%	$2.11	$1.61 ▼ $6.88	$405.20M	0.92	3.24 million shs	2.36 million shs
HLVX HilleVax	$2.09	$2.09	$1.77 ▼ $2.17	$104.79M	0.77	532,880 shs	N/A
KMDA Kamada	$7.76 +2.4%	$7.23	$6.50 ▼ $9.35	$435.89M	0.86	82,164 shs	353,565 shs
LXEO Lexeo Therapeutics	$4.98 +2.9%	$4.66	$3.99 ▼ $10.99	$397.10M	1.46	1.06 million shs	913,839 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	0.00%	+4.65%	+9.76%	+22.95%	-24.24%
HLVX HilleVax	0.00%	0.00%	0.00%	0.00%	+0.48%
KMDA Kamada	0.00%	+4.26%	+7.52%	-3.19%	+3.13%
LXEO Lexeo Therapeutics	0.00%	+0.62%	+3.20%	+2.76%	+2.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$2.31 +2.7%	$2.11	$1.61 ▼ $6.88	$405.20M	0.92	3.24 million shs	2.36 million shs
HLVX HilleVax	$2.09	$2.09	$1.77 ▼ $2.17	$104.79M	0.77	532,880 shs	N/A
KMDA Kamada	$7.76 +2.4%	$7.23	$6.50 ▼ $9.35	$435.89M	0.86	82,164 shs	353,565 shs
LXEO Lexeo Therapeutics	$4.98 +2.9%	$4.66	$3.99 ▼ $10.99	$397.10M	1.46	1.06 million shs	913,839 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	0.00%	+4.65%	+9.76%	+22.95%	-24.24%
HLVX HilleVax	0.00%	0.00%	0.00%	0.00%	+0.48%
KMDA Kamada	0.00%	+4.26%	+7.52%	-3.19%	+3.13%
LXEO Lexeo Therapeutics	0.00%	+0.62%	+3.20%	+2.76%	+2.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	2.88	Moderate Buy	$11.77	409.49% Upside
HLVX HilleVax	0.00	N/A	N/A	N/A
KMDA Kamada	3.00	Buy	$13.00	67.53% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$18.75	276.51% Upside

Current Analyst Ratings Breakdown

Latest HLVX, KMDA, CMPX, and LXEO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	CMPX Compass Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
7/30/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/21/2026	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/21/2026	KMDA Kamada	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
7/17/2026	CMPX Compass Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/10/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	CMPX Compass Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$5.00
6/25/2026	KMDA Kamada	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
6/25/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	489.42	N/A	N/A	$1.11 per share	2.08
HLVX HilleVax	N/A	N/A	N/A	N/A	$3.10 per share	N/A
KMDA Kamada	$180.46M	2.47	$0.63 per share	12.41	$4.68 per share	1.66
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$3.38 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$66.49M	-$0.40	N/A	N/A	N/A	N/A	-38.71%	-34.72%	11/4/2026 (Estimated)
HLVX HilleVax	-$147.27M	-$1.43	N/A	N/A	N/A	N/A	-34.29%	-28.50%	N/A
KMDA Kamada	$20.20M	$0.38	20.42	12.93	0.67	11.60%	8.37%	5.85%	N/A
LXEO Lexeo Therapeutics	-$99.96M	-$1.15	N/A	N/A	N/A	N/A	-41.85%	-38.03%	N/A

Latest HLVX, KMDA, CMPX, and LXEO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KMDA Kamada	$0.1125	$0.16	+$0.0475	$0.16	$50.84 million	$54.92 million
8/12/2026	Q2 2026	LXEO Lexeo Therapeutics	-$0.2852	-$0.30	-$0.0148	-$0.30	N/A	N/A
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
HLVX HilleVax	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	$0.19	2.46%	N/A	50.00%	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	11.22	11.22
HLVX HilleVax	N/A	26.39	26.39
KMDA Kamada	N/A	4.06	2.29
LXEO Lexeo Therapeutics	N/A	13.89	13.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
HLVX HilleVax	86.42%
KMDA Kamada	20.38%
LXEO Lexeo Therapeutics	60.67%

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	18.70%
HLVX HilleVax	24.90%
KMDA Kamada	36.10%
LXEO Lexeo Therapeutics	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	20	180.09 million	146.41 million	Not Optionable
HLVX HilleVax	20	50.14 million	37.66 million	Not Optionable
KMDA Kamada	360	57.51 million	36.75 million	Optionable
LXEO Lexeo Therapeutics	58	82.05 million	80.41 million	Not Optionable

HLVX, KMDA, CMPX, and LXEO Headlines

Recent News About These Companies

Lexeo Therapeutics (NASDAQ:LXEO) Downgraded to "Strong Sell" Rating by Wall Street Zen

August 15 at 2:06 AM | americanbankingnews.com

Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Lowered by Wall Street Zen

August 15 at 2:05 AM | marketbeat.com

Hennion & Walsh Asset Management Inc. Invests $1.24 Million in Lexeo Therapeutics, Inc. $LXEO

August 13, 2026 | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Hits Estimates

August 12, 2026 | marketbeat.com

Lexeo Therapeutics advances gene therapy and gains RMAT status

August 12, 2026 | tipranks.com

Lexeo Therapeutics Announces SUNRISE-FA 2 Trial Initiation for LX2006 and Receives FDA RMAT Designation for LX2020

August 12, 2026 | quiverquant.comQ

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

August 12, 2026 | globenewswire.com

Dimensional Fund Advisors LP Increases Holdings in Lexeo Therapeutics, Inc. $LXEO

August 12, 2026 | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Brokerages

August 10, 2026 | marketbeat.com

Lexeo Therapeutics (LXEO) Projected to Release Earnings on Thursday

August 6, 2026 | marketbeat.com

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

August 5, 2026 | globenewswire.com

Lexeo Therapeutics, Inc. $LXEO Shares Sold by Janus Henderson Group PLC

August 3, 2026 | marketbeat.com

Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Down 5.06%

July 31, 2026 | aaii.comA

Lexeo Therapeutics (NASDAQ:LXEO) Upgraded to Strong-Buy at Chardan Capital

July 31, 2026 | marketbeat.com

Orbimed Advisors LLC Purchases 1,477,450 Shares of Lexeo Therapeutics, Inc. $LXEO

July 27, 2026 | marketbeat.com

Lexeo Therapeutics, Inc. $LXEO Shares Sold by Octagon Capital Advisors LP

July 27, 2026 | marketbeat.com

Spruce Street Capital LP Acquires 753,593 Shares of Lexeo Therapeutics, Inc. $LXEO

July 25, 2026 | marketbeat.com

Affinity Asset Advisors LLC Increases Stock Position in Lexeo Therapeutics, Inc. $LXEO

July 25, 2026 | marketbeat.com

Lexeo’s SUNRISE-FA 2 Trial Puts Gene Therapy for Rare Heart Disease in Investor Focus

July 22, 2026 | tipranks.com

What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple

July 15, 2026 | finance.yahoo.com

Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update?

July 2, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLVX, KMDA, CMPX, and LXEO Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$2.31 +0.06 (+2.67%)

As of 04:00 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

HilleVax NASDAQ:HLVX

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Kamada NASDAQ:KMDA

$7.76 +0.18 (+2.37%)

As of 04:00 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Lexeo Therapeutics NASDAQ:LXEO

$4.98 +0.14 (+2.89%)

As of 04:00 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HLVX, KMDA, CMPX, and LXEO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HLVX, KMDA, CMPX, and LXEO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HLVX, KMDA, CMPX, and LXEO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLVX, KMDA, CMPX, and LXEO Company Descriptions

Compass Therapeutics NASDAQ:CMPX

HilleVax NASDAQ:HLVX

Kamada NASDAQ:KMDA

Lexeo Therapeutics NASDAQ:LXEO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HLVX, KMDA, CMPX, and LXEO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HLVX, KMDA, CMPX, and LXEO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HLVX, KMDA, CMPX, and LXEO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLVX, KMDA, CMPX, and LXEO Company Descriptions

Compass Therapeutics NASDAQ:CMPX

HilleVax NASDAQ:HLVX

Kamada NASDAQ:KMDA

Lexeo Therapeutics NASDAQ:LXEO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools